Thermo Fisher Scientific Inc. (TMO)
NYSE$519.57
Market Cap
$196.01B
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
386 of 924
Rank in Industry
21 of 49
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
TMO Insider Trading Activity
TMO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $11,038 | 2 | 5 |
Sells | $181,595,604 | 41 | 95 |
Related Transactions
| Chai Nelson | director | 2 | $11,038 | 1 | $8,449 | $2,589 |
| Pettiti Gianluca | Executive Vice President | 0 | $0 | 3 | $523,980 | $-523,980 |
| Holmes Joseph R. | VP & Chief Accounting Officer | 0 | $0 | 1 | $525,484 | $-525,484 |
| Shafer Michael D | Executive Vice President | 0 | $0 | 1 | $945,038 | $-945,038 |
| Britt Lisa P. | Sr. VP and Chief HR Officer | 0 | $0 | 1 | $2.22M | $-2.22M |
| Boxer Michael A | SVP and General Counsel | 0 | $0 | 4 | $5.47M | $-5.47M |
| Lowery Frederick M. | Executive Vice President | 0 | $0 | 1 | $9.73M | $-9.73M |
| Lagarde Michel | Executive Vice President & COO | 0 | $0 | 1 | $11.8M | $-11.8M |
| Williamson Stephen | Sr. VP and CFO | 0 | $0 | 3 | $24.54M | $-24.54M |
| CASPER MARC N | Chairman & CEO | 0 | $0 | 25 | $125.82M | $-125.82M |
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, …
Insider Activity of Thermo Fisher Scientific Inc.
Over the last 12 months, insiders at Thermo Fisher Scientific Inc. have bought $11,038 and sold $181.6M worth of Thermo Fisher Scientific Inc. stock.
On average, over the past 5 years, insiders at Thermo Fisher Scientific Inc. have bought $6,571 and sold $182.64M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Chai Nelson (director) — $11,038.
The last purchase of 4 shares for transaction amount of $2,144 was made by Chai Nelson (director) on 2024‑12‑09.
List of Insider Buy and Sell Transactions, Thermo Fisher Scientific Inc.
| 2025-03-10 | Sale | Boxer Michael A | SVP and General Counsel | 3,775.48 0.001% | $532.52 | $2.01M | -2.39% | |
| 2025-03-05 | Sale | CASPER MARC N | Chairman & CEO | 2,450 0.0006% | $516.82 | $1.27M | -0.62% | |
| 2025-03-05 | Sale | CASPER MARC N | Chairman & CEO | 8,000 0.0021% | $520.02 | $4.16M | -0.62% | |
| 2025-03-04 | Sale | CASPER MARC N | Chairman & CEO | 2,891 0.0008% | $514.18 | $1.49M | +1.04% | |
| 2025-03-04 | Sale | CASPER MARC N | Chairman & CEO | 10,000 0.0026% | $516.67 | $5.17M | +1.04% | |
| 2025-03-03 | Sale | Shafer Michael D | Executive Vice President | 1,780 0.0005% | $530.92 | $945,038 | -0.52% | |
| 2025-02-24 | Sale | Lowery Frederick M. | Executive Vice President | 18,300 0.0048% | $531.81 | $9.73M | -2.25% | |
| 2025-02-19 | Sale | Chai Nelson | director | 16 <0.0001% | $528.09 | $8,449 | +0.01% | |
| 2025-02-04 | Sale | Williamson Stephen | Sr. VP and CFO | 9,825 0.0025% | $585.59 | $5.75M | -8.71% | |
| 2025-02-04 | Sale | Pettiti Gianluca | Executive Vice President | 300 <0.0001% | $585.59 | $175,677 | -8.71% | |
| 2025-02-03 | Sale | Williamson Stephen | Sr. VP and CFO | 9,825 0.0025% | $593.13 | $5.83M | -10.54% | |
| 2024-12-09 | Chai Nelson | director | 4 <0.0001% | $535.93 | $2,144 | -0.53% | ||
| 2024-12-03 | Sale | CASPER MARC N | Chairman & CEO | 10,000 0.0026% | $532.20 | $5.32M | -0.26% | |
| 2024-12-02 | Sale | CASPER MARC N | Chairman & CEO | 10,000 0.0026% | $530.26 | $5.3M | +0.71% | |
| 2024-11-08 | Sale | CASPER MARC N | Chairman & CEO | 9,000 0.0024% | $552.86 | $4.98M | -3.66% | |
| 2024-11-07 | Sale | CASPER MARC N | Chairman & CEO | 8,700 0.0023% | $557.14 | $4.85M | -4.32% | |
| 2024-11-07 | Sale | CASPER MARC N | Chairman & CEO | 10,000 0.0026% | $557.76 | $5.58M | -4.32% | |
| 2024-11-07 | Chai Nelson | director | 16 <0.0001% | $555.89 | $8,894 | -4.32% | ||
| 2024-11-06 | Sale | CASPER MARC N | Chairman & CEO | 10,000 0.0026% | $558.12 | $5.58M | -4.90% | |
| 2024-11-01 | Sale | CASPER MARC N | Chairman & CEO | 5,850 0.0015% | $557.89 | $3.26M | -4.52% |
Total: 561
*Gray background shows transactions not older than one year
Insider Historical Profitability
11.85%
| CASPER MARC N | Chairman & CEO | 115174 0.0305% | $59.84M | 1 | 153 | +23.48% |
| Chai Nelson | director | 14252 0.0038% | $7.4M | 2 | 1 | |
| Boxer Michael A | SVP and General Counsel | 10816 0.0029% | $5.62M | 1 | 6 | +4.44% |
| SPERLING SCOTT M | director | 80440 0.0213% | $41.79M | 1 | 4 | +21.21% |
| Herrema Gregory J. | Senior Vice President | 29459 0.0078% | $15.31M | 1 | 8 | +20.77% |
*Gray background shows insiders who have made transactions during last year
TMO Institutional Investors: Active Positions
| Increased Positions | 1,171 | +39.43% | 21M | +6.33% |
| Decreased Positions | 1,309 | -44.07% | 20M | -5.91% |
| New Positions | 275 | New | 4M | New |
| Sold Out Positions | 212 | Sold Out | 2M | Sold Out |
| Total Postitions | 2,832 | -4.65% | 341M | +0.42% |
TMO Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $17.36M | 8.82% | 33.25M | +196,864 | +0.6% | 2024-12-31 |
| Blackrock, Inc. | $15.05M | 7.65% | 28.84M | -321,216 | -1.1% | 2024-12-31 |
| State Street Corp | $8.59M | 4.36% | 16.45M | +129,067 | +0.79% | 2024-12-31 |
| Morgan Stanley | $6M | 3.05% | 11.49M | +348,741 | +3.13% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $5.7M | 2.9% | 10.92M | -56,433 | -0.51% | 2024-12-31 |
| Capital World Investors | $4.92M | 2.5% | 9.43M | +104,343 | +1.12% | 2024-12-31 |
| Jpmorgan Chase & Co | $4.66M | 2.37% | 8.92M | +2M | +34.98% | 2024-12-31 |
| Capital Research Global Investors | $4.14M | 2.1% | 7.92M | -266,957 | -3.26% | 2024-12-31 |
| Geode Capital Management, Llc | $4.1M | 2.08% | 7.86M | +197,442 | +2.58% | 2024-12-31 |
| Fmr Llc | $3.31M | 1.68% | 6.34M | -2M | -19.55% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.